Healthcare News 3 October 2025

Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Strong Q3 Earnings Propel Stock Higher Guardant’s latest quarterly report blew past Wall Street’s expectations, sparking a sharp rally in its shares. For Q3 2025, revenue was $265.2 million, a 39% jump from a year ago and well above the

30 October 2025

Biotechnology·Earnings Reports·Healthcare·Stocks

VSee Health (VSEE) Stock Rockets 75% on $10M Hospital Teleradiology Deal – Is This Telehealth’s Next Big Winner?

VSee Health (VSEE) Skyrockets 200% on Federal Telehealth Approval – Will the Surge Last?

Stock soars on federal approval, then steadies at new highs VSee Health’s stock (NASDAQ: VSEE) has experienced a whirlwind rally over the past two trading days. On October 28, shares of the telehealth upstart skyrocketed on news of a coveted

29 October 2025

Healthcare·Investments·Stock Market

UnitedHealth Stock Rallies to $364 – Will UNH’s 2025 Comeback Last or Fade?

Stock Price Snapshot: October 2025 Rebound UnitedHealth stock has seen volatile swings in 2025, but recent weeks brought a measure of relief. As of Oct. 21, shares trade around $364, up from the lows hit earlier in the year. On

21 October 2025

Financial Analysis·Healthcare·Investing·Stock Market

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics (NASDAQ: BEAM) Globenewswire. – Price (Oct 21, 2025): ~$30 per share (about +17% recently) ts2.tech. – Sector: Biotechnology (precision gene editing) Globenewswire. – Recent News: FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations to

21 October 2025

Analyst Ratings·Biotechnology·Healthcare·Investment·Stock Market

DocGo (NASDAQ: DCGO) Stock Rockets After Virtual Care Acquisition – Can the Rally Last?

Stock Surges on SteadyMD Acquisition DocGo’s shares jumped more than 34% in after-hours trading on Oct. 20, 2025, after the company announced it would acquire SteadyMD, a virtual care platform. According to an Investing.com report, DocGo stock “surged 34.6% in

21 October 2025

Healthcare·Investing·Market News·Mergers & Acquisitions·Stocks

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Key Facts – October 18, 2025 GILD Stock Price Rallies to New Heights Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the high $110s earlier in October, GILD spiked 4.2%

18 October 2025

Biotechnology·Healthcare·Investment Analysis·Pharmaceuticals·Stock Market

INVO Fertility (IVF) Stock’s Wild 90% Surge Amid IVF Boom – What’s Behind the Frenzy?

Stock Price Surge and Aftermath INVO Fertility’s stock took Wall Street by surprise this week with a massive one-day surge. On October 16, shares of the micro-cap fertility clinic operator opened around $0.75 and skyrocketed nearly 90% by day’s end,

17 October 2025

Healthcare·Investing·Stock Market

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

NVO Stock Slides as Weight-Loss Hype Cools Novo Nordisk’s stock has been on a wild ride. After becoming Europe’s most valuable company in 2022–2023 on the back of its smash-hit obesity drug Wegovy, the Danish pharma giant has seen its

17 October 2025

Healthcare·Industry News·Pharmaceuticals·Stock Market

Humana Hit Hard: Judge Upholds Medicare Advantage Star Cut, Stock Slides

Lawsuit Outcome and Court Ruling Humana (the second‐largest Medicare Advantage insurer) sued CMS in July after its star rating unexpectedly plunged. The insurer argued that CMS unfairly flagged three interpreter calls as failures (with no callback allowed), causing a 4.5-to-3.5

15 October 2025

Healthcare·Insurance·Legal News·Stock Market

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

Background: J&J’s Three-Way Split Strategy Johnson & Johnson, a healthcare conglomerate, historically consisted of consumer health, pharmaceutical (Innovative Medicine), and medical technology divisions. In 2023 J&J spun off its consumer products (Tylenol, Band-Aid, Neutrogena, etc.) into a new public company,

14 October 2025

Business News·Corporate Strategy·Healthcare·Industry Trends

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

Stock Performance: From Laggard to Late-September Lift For much of 2025, Pfizer’s stock was stuck in a rut – but that changed dramatically as Q4 approached. By late September, PFE had drifted down near multi-year lows around $23, reflecting a

6 October 2025

Business News·Healthcare·Investment Trends·Pharma Industry·Stock Market

Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Company Overview and Recent Developments Tarsus Pharmaceuticals (NASDAQ: TARS) is a biopharma focused on eye care. Its flagship product XDEMVY (lotilaner ophthalmic solution) was FDA-approved in July 2023 as the first-ever treatment for Demodex blepharitis (eyelid inflammation caused by Demodex mites) Globenewswire. Tarsus

3 October 2025

Biotechnology·Healthcare·Investment News·Pharmaceuticals·Stock Market

Healthcare News 3 October 2025 - 30 October 2025